Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female

Vaccination for COVID19 infection is in full swing all around the world and while the vaccines are considered overall safe, many cutaneous and extracutaneous adverse effects have been reported after their use. Local injection-site reactions are the commonest adverse effect described with the use of these vaccines. We describe a case of Sweet syndrome in an elderly female after the first dose of Oxford-AstraZeneca COVID-19 vaccine (AZD1222).

Automated summary

Vaccination for COVID-19 has led to various cutaneous and extracutaneous adverse effects, with local injection-site reactions being the most common. This study reports a case of Sweet syndrome in an elderly female following the first dose of the Oxford-AstraZeneca COVID-19 vaccine (AZD1222).